Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tracking 250 men to see how long new prostate cancer combo works

NCT ID NCT06380738

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study follows 250 men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. Researchers will observe how long patients continue taking the combination of two medications (olaparib and abiraterone) in real-world medical settings. The goal is to understand how well this treatment combination works outside of controlled clinical trials and which patients benefit most.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Aschaffenburg, Germany

  • Research Site

    RECRUITING

    Augsburg, Germany

  • Research Site

    RECRUITING

    Bergisch Gladbach, Germany

  • Research Site

    RECRUITING

    Berlin, Germany

  • Research Site

    RECRUITING

    Bonn, Germany

  • Research Site

    RECRUITING

    Cologne, Germany

  • Research Site

    RECRUITING

    Dresden, Germany

  • Research Site

    RECRUITING

    Duisburg, Germany

  • Research Site

    RECRUITING

    Eisenach, Germany

  • Research Site

    RECRUITING

    Eisleben Lutherstadt, Germany

  • Research Site

    RECRUITING

    Frankfurt, Germany

  • Research Site

    RECRUITING

    Greifswald, Germany

  • Research Site

    RECRUITING

    Halle, Germany

  • Research Site

    RECRUITING

    Hamburg, Germany

  • Research Site

    RECRUITING

    Hanover, Germany

  • Research Site

    RECRUITING

    Heidelberg, Germany

  • Research Site

    RECRUITING

    Heinsberg, Germany

  • Research Site

    RECRUITING

    Herzogenaurach, Germany

  • Research Site

    RECRUITING

    Leipzig, Germany

  • Research Site

    RECRUITING

    Lübeck, Germany

  • Research Site

    RECRUITING

    Lüneburg, Germany

  • Research Site

    RECRUITING

    Magdeburg, Germany

  • Research Site

    RECRUITING

    Marburg, Germany

  • Research Site

    RECRUITING

    Mülheim, Germany

  • Research Site

    RECRUITING

    Münster, Germany

  • Research Site

    RECRUITING

    Neunkirchen, Germany

  • Research Site

    RECRUITING

    Nuremberg, Germany

  • Research Site

    RECRUITING

    Rüsselsheim am Main, Germany

  • Research Site

    RECRUITING

    Saalfeld, Germany

  • Research Site

    RECRUITING

    Speyer, Germany

  • Research Site

    RECRUITING

    Trier, Germany

  • Research Site

    RECRUITING

    Tübingen, Germany

  • Research Site

    RECRUITING

    Westerstede, Germany

  • Research Site

    RECRUITING

    Wetzlar, Germany

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER